Home » QIDP Antibiotics » Page 17

Category Archives: QIDP Antibiotics

All AllPhasePharma blogs dealing predominantly with a QIDP antibiotic

Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study

Posted on by — No Comments ↓

Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1]  This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into Continue reading Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study→

What is the “Niche” for Ceftolozane / Tazobactam?

Posted on by — 2 Comments ↓

There are currently a total of 6 beta-lactam + beta-lactamase inhibitor combinations in clinical trials. It will be a steep learning curve for the pharma reps (and physicians) to understand the resistance classifications, the confusing ESBL definitions, the CRE nomenclature, and how this all matters in clinical practice, on the Continue reading What is the “Niche” for Ceftolozane / Tazobactam?→

BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3

Posted on by — No Comments ↓

The pleuromutilins are a relatively ‘old’ class of antibiotics that have seen much use in veterinary but not in human medicine.  According to EMA, Tiamulin is an “essential antibiotic” for the control of dysentery in pigs which is caused by Brachyspira hyodysenteriae, a macrolide-resistant pathogen.[1]  Retapamulin / Altabax® was introduced Continue reading BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3→